Baird served as the co-lead manager of this transaction.
AboutCerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”) recently announced a public offering of 7,368,422 units, generating gross proceeds of $21.0 million. Each unit consists of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The net proceeds will be used for general corporate purposes, including research and development, selling, general and administrative as well as manufacturing expenses.
Cerus is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company’s near-term goal is to continue pursuing regulatory approval of the INTERCEPT platelet and plasma systems in the United States and to continue development of the INTERCEPT red blood cell system in pursuit of regulatory approvals worldwide.
This transaction is Baird’s third for Cerus since 2006.
For additional information about this transaction, please contact:
- November 2010
- Cerus Corporation
- Target Location
- North America